Cambridge Cognition Holdings PLC Issue of Equity and Total Voting Rights
26 July 2024 - 4:00PM
RNS Regulatory News
RNS Number : 9167X
Cambridge Cognition Holdings PLC
26 July 2024
26 July 2024
Cambridge Cognition Holdings
plc
("Cambridge Cognition", the "Company" or the
"Group")
Issue of
Equity and Total Voting Rights
Cambridge Cognition Holdings plc
(AIM: COG), which develops and markets digital solutions to assess
brain health, announces that further
to the announcement on 12 October 2022 regarding the acquisition of
eClinicalHealth Limited ("Clinpal"), the Company has today issued
229,984 new ordinary shares of £0.01 each in the share capital of
the Company ("New Ordinary Shares") at an issue price of 132.97
pence per New Ordinary Share to certain shareholders of Clinpal,
representing approximately £0.3m of the contingent
consideration. No further consideration is due to former
shareholders of Clinpal.
Admission and Total Voting
Rights
Application has been made to the
London Stock Exchange for the New Ordinary Shares to be admitted to
trading on AIM ("Admission") and it is expected that such Admission
will take place on or around 8:00 a.m. on or around 31
July 2024.
In accordance with the provision of
the Disclosure Guidance and Transparency Rules of the Financial
Conduct Authority, the Company confirms that, following the issue
of the New Ordinary Shares, its issued ordinary share capital will
comprise 41,940,413 Ordinary Shares. There
are no shares held in treasury therefore the total number of voting
rights in the Company is 41,940,413. This figure may be used by
shareholders as the denominator for the calculation by which they
will determine if they are required to notify their interest in, or
a change to their interest in Cambridge Cognition under the FCA's
Disclosure and Transparency Rules.
Enquiries:
|
Cambridge Cognition Holdings plc
Matthew Stork, Chief Executive
Officer
Stephen Symonds, Chief Financial
Officer
|
Tel: 012 2381 0700
press@camcog.com
|
|
Panmure Liberum Limited (NOMAD and Joint
Broker)
Emma Earl / Freddy Crossley /
Mark Rogers
Rupert Dearden
|
Tel: 020 7886 2968
(Corporate Finance)
(Corporate Broking)
|
|
Dowgate Capital Limited (Joint
Broker)
David Poutney / Nicholas
Chambers
|
Tel: 020 3903 7715
|
|
Hudson Sandler (Financial PR and IR)
Dan de Belder / Hattie
Dreyfus
|
Tel: 020 7796 4133
cog@hudsonsandler.com
|
|
|
Notes to Editors
About Cambridge Cognition
Cambridge Cognition is a technology
company developing digital health products to better understand,
detect and treat conditions affecting brain health. The Company's
software products assess cognitive health in patients worldwide to
improve clinical trial outcomes, identify and stratify patients
early and improve global efficiency in pharmaceutical and
healthcare industries.
For further information
visit: https://cambridgecognition.com/
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact
rns@lseg.com or visit
www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our
Privacy
Policy.
END
IOEPPUUCMUPCGQA
Cambridge Cognition (LSE:COG)
Historical Stock Chart
From Nov 2024 to Dec 2024
Cambridge Cognition (LSE:COG)
Historical Stock Chart
From Dec 2023 to Dec 2024
